Document is current
Any future updates will be listed below
-
Authors
Marzano, Angelo Valerio https://orcid.org/0000-0002-8160-4169
Bartoletti, Michele https://orcid.org/0000-0002-1099-3283
Bettoli, Vincenzo https://orcid.org/0000-0002-2760-4600
Bianchi, Luca
Chiricozzi, Andrea https://orcid.org/0000-0002-6739-0387
Clerici, Mario https://orcid.org/0000-0001-5920-6191
Dapavo, Paolo
Dini, Valentina https://orcid.org/0000-0002-8537-1999
Foti, Caterina https://orcid.org/0000-0001-6196-9788
Magnoni, Cristina https://orcid.org/0000-0002-6081-4925
Megna, Matteo https://orcid.org/0000-0003-1803-2046
Micali, Giuseppe https://orcid.org/0000-0002-5157-3939
Molinelli, Elisa https://orcid.org/0000-0002-7939-0026
Prignano, Francesca https://orcid.org/0000-0002-5997-2045
-
Funding
Funding for this research was provided by:
Università degli Studi di Milano
- License Information
-
More Information
Article History
Received: 23 January 2025
Revised: 23 January 2025
Accepted: 12 February 2025
First Online: 28 February 2025
Declarations
:
: AVM received consultancy/advisory boards disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. FP served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Eli Lilly, Janssen, Novartis, Biogen, Sanofi Genzyme, UCB, Boehringer Ingelheim, Pfizer and Bristol Meyers Squibb. VB served as a board member, speaker or investigator for AbbVie, Cantabria, Galderma, General Topics, LaRoche Posay, Ganassini, L’Oreal, Novartis, Sanofi and UCB, and received grant for their institution from AbbVie. EM served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Janssen, Novartis, UCB and Boehringer Ingelheim. CF served as an investigator and or/speaker for AbbVie, Amgen, Boehringer Ingelheim, Incyte, LEO Pharma, Ely Lilly, Pfizer, Novartis, Pfizer and Sanofi. CM served as a member of advisory boards, as a consultant and has participated in sponsored clinical trials for AbbVie, Almirall, Integra LifeSciences, MedSkin Solutions, Novartis, Sanofi, Fidia Farmaceutici S.p.A, GSK and Holostem Srl. VD served as an advisory board member, or consultant and has received fees and speaker's honoraria or has participated in sponsored clinical trials for AbbVie, Almirall, Convatec, Eli Lilly, Leopharma, Johnson & Johnson, Novartis, UCB and Boehringer Ingelheim. LB served as member of advisory boards, consultant and received fees and speaker's honoraria or PI in clinical trials for AbbVie, Janssen, Novartis, UCB, Boehringer Ingelheim. Novartis, Sanofi, Biogen, Pfizer, La Roche Posay and Cantabria. GM has received consultancy/advisory boards disease-relevant honoraria from Boehringer Ingelheim, Bristol Myers Squibb, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. MM acted as a speaker or consultant for AbbVie, Amgen, Almirall, Janssen, Eli Lilly, Leo Pharma, Novartis and UCB. MB received advisory board disease-relevant honoraria from Novartis. MC and AC declare no conflict of interest.
: Not applicable.
